BV2
BV2 is a delivery peptide that binds to BVES, with a Ka of 2.03 μM for the BVES target. BV2 specifically binds to the extracellular domain of BVES, achieving muscle homing and cellular internalization via caveolae-mediated endocytosis. When BV2 is modified on the surface of exosomes by PMO, it enhances dystrophin restoration in the peripheral muscles and myocardium of dystrophin-deficient mice. BV2 is applicable to research related to Duchenne muscular dystrophy and muscle atrophy.
For research use only. We do not sell to patients.
- Formula: C57H98N18O17
- Molecular Weight:1307.50
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
BV2 (15.625-2000 nM) binds specifically to the extracellular domain of BVES with a dissociation constant of 2.03 μM[1].
BV2 (0.5-10 μg/mL; 15 min-6 h) is taken up by C2C12 mouse myoblasts in a dose- and energy-dependent manner, localizes to the cytoplasm and early endosomes, and is internalized primarily via caveolae-mediated endocytosis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
BV2-mCherry (20 mg/kg; i.v.; single dose) effectively delivers mCherry protein to peripheral skeletal muscle cells in wild-type C57BL/6 mice after single intravenous administration of 20 mg/kg, with minimal accumulation in non-muscle tissues[1].
Rhodamine B-labelled BV2 (100 μg per microneedle patch; local implantation; single application; 2 hours), delivered via HA microneedle implantation, effectively accumulates in and is internalized by local skeletal muscle cells in wild-type C57BL/6 mice after a single 2-hour application of a 100 μg-loaded patch[1].
BV2-mCherry (150 μg per microneedle patch; local implantation; single application), delivered via HA microneedle implantation, effectively promotes mCherry protein delivery to skeletal muscle layers in wild-type C57BL/6 mice after a single application of a 150 μg-loaded patch[1].
BV2-E31R (50 μg per microneedle patch; local implantation; 3 times per week; 2 weeks), delivered via HA microneedle implantation at 50 μg per patch 3 times weekly for 2 weeks, significantly increases muscle mass and myofibre size in both immobilization- and denervation-induced skeletal muscle atrophy mice[1].
EXOBV2&PMO (12.5 mg/kg/week PMO equivalent; i.v.; weekly; 3 weeks), administered intravenously at 12.5 mg/kg/week PMO equivalent for 3 weeks, significantly restores dystrophin expression (up to 10-fold increase in triceps), enhances muscle grip strength, and reduces muscle damage in adult mdx mice[1].
EXOBV2&PMO (25 mg/kg/week PMO equivalent; i.v.; weekly; 3 weeks), administered intravenously at 25 mg/kg/week PMO equivalent for 3 weeks, achieves near-normal dystrophin restoration in peripheral muscles, partial cardiac dystrophin restoration, and significant phenotypic rescue (improved grip strength, reduced muscle damage) in adult DKO mice without detectable organ toxicity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (adult)[1]
-
Dosage:10 mg/kg
-
Administration:i.v.; single dose
-
Result:Detected significantly higher fluorescence signals in the heart and skeletal muscles (including diaphragm and abdominal muscles) and weaker signals in liver compared to a control peptide.
Chemical Information
-
Molecular Weight 1307.50
-
Formula C57H98N18O17
-
Sequence
Ser-Ser-Val-Thr-Arg-Val-Gly-Tyr-Leu-Arg-Gly-Ile
-
Sequence Shortening
SSVTRVGYLRGI
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)